Compare COFS & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | COFS | CBIO |
|---|---|---|
| Founded | 1898 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 537.5M |
| IPO Year | 1995 | 2013 |
| Metric | COFS | CBIO |
|---|---|---|
| Price | $33.48 | $17.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $34.00 | $26.67 |
| AVG Volume (30 Days) | 64.1K | ★ 170.0K |
| Earning Date | 04-24-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $227,624,000.00 | $18,500.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | $279.20 |
| P/E Ratio | $19.10 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.10 | $8.72 |
| 52 Week High | $35.00 | $27.41 |
| Indicator | COFS | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 55.82 |
| Support Level | $29.83 | $16.77 |
| Resistance Level | $33.58 | $17.93 |
| Average True Range (ATR) | 0.70 | 1.00 |
| MACD | -0.12 | 0.14 |
| Stochastic Oscillator | 21.24 | 69.06 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.